Gossamer Partners With Chiesi To Accelerate Seralutinib Development
Cash Will Fund Trial In Second, Larger Indication
Already in Phase III for PAH, Gossamer said it can take seralutinib into Phase III for PH-ILD at least four years earlier than planned under its alliance with respiratory disease expert Chiesi.
